CN Patent

CN101287452A — 包含1-（4-氯苯胺基）-4-（4-吡啶基甲基）-2,3-二氮杂萘和pH调节剂的固体药物组合物

Assigned to Novartis AG · Expires 2008-10-15 · 18y expired

What this patent protects

本发明涉及药物组合物，该药物组合物包含pH依赖的药物化合物1－(4－氯苯胺基)－4－(4－吡啶基甲基)－2，3－二氮杂萘和pH调节剂。

USPTO Abstract

本发明涉及药物组合物，该药物组合物包含pH依赖的药物化合物1－(4－氯苯胺基)－4－(4－吡啶基甲基)－2，3－二氮杂萘和pH调节剂。

Drugs covered by this patent

Wayrilz (RILZABRUTINIB) · Genzyme Corp

Patent Metadata

Patent number: CN101287452A
Jurisdiction: CN
Classification: —
Expires: 2008-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.